Working through growth concerns, biotechnology company Gilead Sciences finally did what everyone was waiting for them to do: make an acquisition. The target is Kite Pharma for which Gilead will pay $11 billion to acquire.
Kite’s value is tied to a new cancer treatment that could soon be available in the United States and Europe called CAR-T. It works by genetically modifying a persons own T-cells to better attack and control certain cancers. Analysts think that within five years the treatment could bring $1.7 billion in sales.
Gilead came to prominence by developing the most effective drugs for treating HIV, a franchise still very much in tact at the company. In 2011 Pharmasset was acquired for $11 billion in order to gain access to its treatments for Hepatitis C while those treatments were still seeking approval. The acquisition was a home run. Gilead’s Hepatitis C business did $19 billion in 2015. However, a backlash over high prices and the one time nature of the treatment means that that portion of Gilead’s business is in decline. Last year, it did only $15 billion in annual revenue.
The deal should close in the fourth quarter – the same time when Kite’s cancer treatment is expected to receive final approval.
more recommended stories
A Disgraced Harvey Weinstein and a Business Empire in Tatters
It was only a brief time.
Under the Hood of Berkshire Hathaway’s Pilot/Flying J Purchase
Berkshire Hathaway announced last week that.
GE Sells Industrial Solutions Business as New CEO Marks New Direction
General Electric announced that it reached.
Disney’s New Streaming Service Requires Patience From Investors
Disney has decided to take its.